Hefei
China
Anhui Zhifei Longcom Biopharmaceutical Co. LTD.
SARS-CoV-2, heterologous immunisation, recombinant adenovirus type-5-vectored COVID-19 vaccine, protein-subunit-based COVID-19 vaccine, clinical trial